The Huawei Watch D2 is on the horizon and has recently obtained the Chinese medical device license, a crucial step for the device’s commercial release in China. This development follows a year of speculation and rumors about the new wearable. The Watch D2 is expected to be officially launched either in the coming months or alongside Huawei’s Mate 70 flagship smartphone.
The Chinese Medical Device License is a certification that permits a company to market its medical devices within China. To achieve this, the company must register the product in a specific medical database. The license for the Watch D2, according to tipster @UncleKanshan, indicates that the device will be officially known as the “Wrist Ambulatory Blood Pressure Recorder,” suggesting it is the successor to the original Watch D.
The license details reveal three model variants for the Watch D2: LCA-B10, LCA-B11, and LCA-B12. Although the official license does not explicitly state the device’s name, the description and model numbers align with the Watch D2, confirming its identity.
The Watch D2 is equipped with a main unit, a wristband, and a wireless charging base. Notably, the wristband includes an airbag, enabling the device to measure systolic and diastolic blood pressure, as well as pulse rate, for individuals over 18 years old. This functionality allows for multiple health assessments within a 24-hour period, though other features of the smartwatch remain undisclosed.
The first-generation Huawei Watch D featured a 2.5D curved display with a box-like design, a 1.64-inch AMOLED color screen, and a resolution of 456 x 280 pixels.
It was constructed with a durable aluminum alloy frame and included features such as Smart Blood Pressure reminders, ECG analysis, and TruSeen 5.0+, with a battery life of up to 7 days on a single charge. Anticipation is building for the new Watch D2 to see what innovations and improvements it will introduce.